Endure Biotherapeutics (“Endure Bio” ™) in San Diego, California, was founded by Professor Amir Zarrinpar MD, PhD, at the Zarrinpar Laboratory, UCSD. The company is developing engineered engraftable live biotherapeutics for gastrointestinal diseases by genetically engineering man’s native bacteria to express therapeutic compounds (such as anti-inflammatory cytokines). Unlike other GI focused microbiome companies, our biotherapeutics will be targeted to remain resident, delivering potentially curative solutions that endure the host environment.
Company Details
- Employees
- 3
- Founded
- 2018
- Address
- San Diego, California, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.endurebio.com
- Keywords
- live biotherapeutics, synthetic biology, microbiome, Gastrointestinal diseases, orphan drugs, engraftable biotherapeutics, metabolism.
- HQ
- San Diego, California
Endure Biotherapeutics Questions
Endure Biotherapeutics's website is http://www.endurebio.com
Endure Biotherapeutics's LinkedIn profile is https://www.linkedin.com/company/endure-biotherapeutics
Endure Biotherapeutics has
3 employees.
View email and phone details for 3
employees at Endure Biotherapeutics.
Endure Biotherapeutics's industry is
Biotechnology Research
Endure Biotherapeutics's top competitors are
Aluda Pharmaceuticals, Inc.,
Excellos,
Abintus Bio, Inc.,
Origami Therapeutics, Inc.,
Native Microbials, Inc.,
Abreos Biosciences,
Palm Therapeutics,
Abilita Therapeutics, Inc.,
Novoron Bioscience,
Trestle Biotherapeutics.
Endure Biotherapeutics's categories are Biotechnology Research
Endure Biotherapeutics's founding year is 2018
